Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

Journal of Clinical Investigation

Volumn 86, Issue 2, 1990, Pages 385-391

  Weitz, Jeffrey I ^a   Hudoba, Monika ^b   Massel, David ^b   Maraganore, John ^b   Hirsh, Jack ^b  

^a HENDERSON GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

Antithrombin III; Fibrin; Heparin; Thrombin

Indexed keywords

ANTITHROMBIN III; FIBRINOPEPTIDE A; HEPARIN; RADIOISOTOPE; THROMBIN;

ARTICLE; BLOOD CLOT; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

AMINO ACID CHLOROMETHYL KETONES; ANTITHROMBIN III; BLOOD COAGULATION; FIBRIN; FIBRINOPEPTIDE A; HEPARIN; HIRUDIN; HUMAN; IN VITRO; KINETICS; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEIN BINDING; SOLUBILITY; SUPPORT, NON-U.S. GOV'T; THROMBIN;

EID: 0025146426     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI114723     Document Type: Article

References (35)

1. Blomback, B., B. Hessel, D. Hogg, and L. Therkildsen. 1978. A two-step fibrinogen-fibrin transition in blood coagulation. Nature (Lond.). 275:501-505.
2. Seegers, W. H., M. Nieff, and J. A. Shafer. 1945. Note on the adsorption of thrombin on fibrin. Science (Wash. DC). 101:520-521.
3. Liu, C. Y., H. L. Nossel, and K. L. Kaplan. 1979. The binding of thrombin by fibrin. J. Biol. Chem. 254:10421-10425.
4. Wilner, G. D., M. P. Danitz, M. S. Mudd, K. H. Hsieh, and J. W. Fenton II. 1981. Selective immobilization of thrombin by surface bound fibrin. J. Lab. Clin. Med. 97:403-411.
5. Berliner, L. J., Y. Sugawara, and J. W. Fenton II. 1985. Human α-thrombin binding to nonpolymerized fibrin-Sepharose: Evidence for an anionic binding region. Biochemistry. 24:7005-7009.
6. Kaminski, M., and J. McDonagh. 1987. Inhibited thrombins: interactions with fibrinogen and fibrin. Biochem. J. 242:881-887.
7. Vali, Z., and H. A. Scheraga. 1988. Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry. 27:1956-1963.
8. Rosenberg, R. D., and P. S. Damus. 1973. The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 248:6490-6505.
9. Bjork, I., and U. Lindahl. 1982. Mechanism of the anticoagulant action of heparin. Mol. Cell. Biochem. 48:161-182.
10. Danielsson, A., E. Raub, U. Lindahl, and I. Bjork. 1986. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J. Biol. Chem. 261:15467-15473.
11. Olson, S. T. 1988. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Linkage of protease-inhibitorheparin interactions in the reaction with thrombin. J. Biol. Chem. 263:1698-1708.
12. Hogg, P. J., and C. M. Jackson. 1989. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc. Nail. Acad. Sci. USA. 86:3619-3623.
13. Boneu, B., M. R. Buchanan, J. F. Cade, J. Van Ryn, F. F. Fernandez, F. A. Ofosu, and J. Hirsh. 1985. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb. Res. 40:81-89.
14. Marder, V. J., R. L. Soulen, V. Atichartakarn, A. Z. Budzynski, S. Parulekar, J. R. Kim, N. Edward, J. Zahavi, and K. M. Algazy. 1977. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J. Lab. Clin. Med. 89:1018-1029.
15. Bratt, G., E. Tornebohm, S. Gragvist, W. Aberg, and D. Lockner. 1985. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb. Haemostasis. 54:813-817.
16. Holm, H. A., B. Ly, G. F. Handeland, U. Abildgaard, K. E. Amesen, P. Gottschalk, V. Hoeg, M. Aandahl, K. Haugen, F. Laerum, B. Scheel, O. Sortland, and B. Vinje. 1986. Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis. 16 (Suppl. 2):30-37.
17. Lagerstedt, C. I., B. O. Fagher, U. Albrechtsson, C. G. Olsson, and B. W. Oqvist. 1985. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. i:515-518.
18. Hull, R., T. Delmore, E. Genton, J. Hirsh, M. Gent, D. Sackett, D. McLoughlin, and P. Armstrong. 1979. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N. Engl. J. Med. 301:855-858.
19. Yasuda, T., H. K. Gold, J. T. Fallon, R. C. Leinbach, J. L. Guerrero, L. E. Scudder, M. Kanke, D. Shealy, M. J. Ross, D. Collen, and B. S. Coller. 1988. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J. Clin. Invest. 81:1284-1291.
20. Topol, E. J., B. S. George, D. J. Kereiakes, D. C. Stump, R. J. Candela, C. W. Abbotsmith, L. Aronson, A. Pickel, J. M. Boswick, K. L. Lee, et al. 1989. A randomized controlled trial of intravenous plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation. 79:281-286.
21. Maraganore, J., B. Chao, M. L. Joseph, J. Jablonski, and K. L. Ramachandran. 1989. Anticoagulant activity of synthetic hirudin peptides. J. Biol. Chem. 264:8692-8698.
22. Nossel, H. L., I. Yudelman, R. E. Canfield, V. P. Butler, Jr., K. Spanondis, G. D. Wilner, and G. D. Qureshi. 1974. Measurement of fibrinopeptide A in human blood. J. Clin. Invest. 54:43-53.
23. Nossel, H. L., V. P. Butler, Jr., G. D. Wilner, R. E. Canfield, and E. J. Harfenist. 1976. Specificity of antisera to human fibrinopeptide A used in clinical fibrinopeptide A assays. Thromb. Haemostasis. 35:101-109.
24. Canfield, R. E., J. Dean, H. L. Nossel, V. P. Butler, Jr., and G. D. Wilner, 1976. Reactivity of fibrinogen and fibrinopeptide A containing fragments with antisera to fibrinopeptide A. Biochemistry. 15:1203-1209.
25. 1-proteinase inhibitor deficiency. J. Clin. Invest. 78:155-162.
26. Weitz, J. I., M. K. Cruickshank, B. Thong, B. Leslie, M. N. Levine, and T. Eckhardt. 1988. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J. Clin. Invest. 82:1700-1707.
27. 125I-fibrinogen injection. J. Radioanal. Chem. 65:179-188.
28. McFarlane, A. S. 1956. Labelling of plasma proteins with radioactive iodine. Biochem. J 62:135-143.
29. Martin, B. M., W. W. Wasiewski, J. W. Fenton II, and T. C. Detwiler. 1976. Equilibrium binding of thrombin to platelets. Biochemistry. 15:4886-4893.
30. Hull, R. D., G. E. Raskob, J. Hirsh, R. M. Jay, J. R. LeClerc, W. H. Geerts, D. Rosenbloom, D. L. Sackett, C. Anderson. L. Harrison. and M. Gent. 1986. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N. Engl. J. Med. 315:1109-1114.
31. Hirsh, J., W. G. van Arken, A. S. Gallus, C. G. Dollery, J. S. Cade, and W. G. Young. 1976. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 53:691-695.
32. Stone, S. R., and J. Hofsteenge. 1986. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 25:4622-4628.
33. Talbot, M. D., J. Ambler, K. D. Butler, V. S. Findlay, K. A. Mitchell, R. F. Peters, M. F. Tweed, and R. B. Wallis. 1989. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb. Haemostasis. 61:77-80.
34. 2Cl. A selective affinity label for thrombin. Thromb. Res. 14:969-973.
35. Mirshahi, M., J. Soria, C. Soria, F. Faivre, H. Lu, M. Courtney, C. Roitsch, D. Tripier, and J. P. Caen. 1989. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood. 74:1026-1030.